Policy Updates

Read the latest updates on our work to improve women’s health by advocating for policy change.

Featured Articles:

What happened, what the NWHN is doing about it, and how you can help.

On September 28 — the 20th anniversary of FDA’s approval of the abortion pill — we held a socially distanced protest in front of FDA headquarters and delivered the names of all 12,000+ of our petition signers.

Explore policy updates:

  • Filter by Issue:

  • Sort by:

Results for:

What happened, what the NWHN is doing about it, and how you can help.

On September 28 — the 20th anniversary of FDA’s approval of the abortion pill — we held a socially distanced protest in front of FDA headquarters and delivered the names of all 12,000+ of our petition signers.

Celebrity promotions are nothing new – we see them constantly, from athletes endorsing sports equipment to singers promoting skin care brands.

As health care workers inevitably reduce the attention they give to people in labor in order to attend to the pandemic, support persons will be instrumental in making sure mothers and infants receive the care they need.

In the aftermath of the #MeToo movement, conversations about sexual harassment in the workplace must continue, as sexual harassment is a health issue. 

On Monday, reproductive health clinics across the nation withdrew from the federal Title X program rather than submit plans for complying with the Trump administration’s radical new “gag” rule.

At a time when so many states are choosing to take care options away from women, California state legislators are positioned to lead the fight to expand access to reproductive care by making medication abortion available at student health centers...

The appropriations process likely represents the best chance we have to overturn dangerous Trump rules eviscerating Title X.

The NWHN and 42 organizations sent a letter today to the House Energy and Commerce Committee applauding their work on a bipartisan discussion draft to address cosmetics safety.

In 2016, the FDA reclassified transvaginal mesh used to repair pelvic organ prolapse (POP) as a Class III device—the highest risk category—in response to over 20,000 adverse event reports during a three-year period alone.